IRADIMED CORP

Iradimed reported Q1 2026 EPS of $0.49 (expectation $0.46) and revenue of $22 million (expectation $20.8 million), both above forecasts. Despite the strong numbers, the share price fell about 2.7% in premarket trading, possibly due to investor nervousness about other factors. The company sees continued growth in domestic sales and expects further revenue growth from the anticipated FDA approval and launch of the MRidium 3870. Risks remain supply‑chain issues, increased competition and macroeconomic pressure on hospital budgets. » More on de.investing.com

Analysts show a strongly bullish consensus on IRADIMED, with three Buy ratings and a one-year median target near $118–$119 implying roughly 30–34% upside. Freedom Broker initiated coverage with a Buy and $116 target, citing the company's unique non-magnetic MRI-compatible IV infusion pumps and patient monitors, growth in ferromagnetic detection products, and attractive international expansion potential. The firm is described as profitable and dividend-yielding, supporting the positive investment case despite analyst notes that other sectors may offer different risk/return profiles. » More on finance.yahoo.com

Iradimed reported GAAP EPS of $0.54 for Q4 2025 (expectation $0.48) and revenue of $22.7m (expectation $21.6m), with both metrics topping analysts' estimates. The company posted its 18th consecutive record quarter for revenue (+17% year‑on‑year) and full‑year revenue of $83.8m (+14%). The stock rose about 9.4% in premarket trading. Iradimed expects further growth from the launch of the MR‑Infusionspumpe 3870, is targeting a $100m run rate and plans expansion in Europe and Japan, but cites supply‑chain, regulatory and competitive risks. » More on de.investing.com

Riverwater Partners' Micro Opportunities Strategy highlighted IRADIMED CORPORATION (NASDAQ:IRMD) as its top contributor for Q4 and full-year 2025 after the stock rallied nearly 38% in Q4 and about 80% for the year. IRADIMED posted a one-month return of 5.01%, a 52-week gain of 72.38% and closed at $102.00 on December 15, 2025, with a market cap of $1.244 billion. The company reported record Q3 revenue of $21.2 million, up 16% year-over-year. » More on finance.yahoo.com

Iradimed shares closed at $100.55, marking a new all-time high. With a market capitalization of $1.28 billion the P/E ratio is 60.83; the stock rose 75.29% over 12 months. Fundamentals show a gross profit margin of 77.07% and revenue growth of 12.91%, but InvestingPro flags a possible overvaluation versus fair value. Iradimed beat expectations in Q3 2025 (EPS $0.47; revenue $21.2 million) and paid a special dividend of $0.50; the next quarterly results are due in 15 days. » More on de.investing.com